Trastuzumab and fulvestrant combination therapy is one of the treatment options for patients with hormone receptor- and human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer; however, there are limited studies evaluating the efficacy of this combination therapy. | Ozaki et al. BMC Cancer 2022 22 36 https s12885-021-09128-1 RESEARCH Open Access Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2 a retrospective single-center study Yukinori Ozaki1 2 Yosuke Aoyama3 Jun Masuda1 Lina Inagaki1 Saori Kawai1 Tomoko Shibayama1 Tetsuyo Maeda1 Mami Kurata1 Kazuyo Yoshida1 Sumito Saeki1 Mari Hosonaga1 Ippei Fukada1 Fumikata Hara1 Takayuki Kobayashi1 Kokoro Kobayashi1 Satoshi Miyake2 Toshimi Takano1 Takayuki Ueno1 and Shinji Ohno1 Abstract Background Trastuzumab and fulvestrant combination therapy is one of the treatment options for patients with hormone receptor- and human epidermal growth factor receptor 2 HER2 -positive metastatic breast cancer how- ever there are limited studies evaluating the efficacy of this combination therapy. Methods We retrospectively reviewed the data of women with hormone receptor- and HER2-positive metastatic breast cancer who received trastuzumab and fulvestrant combination therapy between August 1997 and August 2020 at the Cancer Institute Hospital. The primary endpoint of this study was progression-free survival and the sec- ondary endpoints were response rate overall survival and safety. Results We reviewed the data of 1612 patients with recurrent or metastatic breast cancer of which 118 patients were diagnosed with hormone receptor- and HER2-positive breast cancer. Of these 28 patients who received tras- tuzumab and fulvestrant combination therapy were eligible for this study. The median treatment line for advanced breast cancer was 6 range 1 14 the median progression-free survival was months 95 confidence interval CI and the median overall survival was months 95 CI . Of the 28 patients partial response was observed in 1 4 stable disease in 17 61 and progressive disease in 10 36 patients. The disease control rate was 64 . Adverse events of grade 3 .
